SOURCE: Equity News Circuit

Equity News Circuit

May 10, 2013 08:20 ET

Free Research Reports on BSX, DNDN, GMCR and PPO Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - May 10, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.

Boston Scientific Corp. (NYSE: BSX) shares spiked 5.73 percent on volume of over 32.0 million shares traded Thursday to close at $8.30 a share. The company announced data from a clinical trial of its Watchman Left Atrial Appendage closure device showed it was "statistically superior to warfarin for preventing cardiovascular death."

Find out more about Boston Scientific including full access to the free equity report at: www.ParagonReport.com/BSX

Dendreon Corporation (NASDAQ: DNDN) shares declined 14.98 percent on volume of over 20.0 million shares traded Thursday to close at $4.03 a share. The company reported sales of its prostate cancer drug, Provenge, totaled $67.6 million for the first quarter of 2013, a decrease of 18 percent year-over-year.

Find out more about Dendreon including full access to the free equity report at: www.ParagonReport.com/DNDN

Green Mountain Coffee Roasters Inc. (NASDAQ: GMCR) shares soared 27.84 percent on volume of over 26.0 million shares traded Thursday to close at $76.04 a share. The company reported a net income of $132.4 million for the first quarter of 2013, an increase of 42 percent when compared to the year ago quarter.

Find out more about Green Mountain Coffee Roasters including full access to the free equity report at: www.ParagonReport.com/GMCR

Polypore International, Inc. (NYSE: PPO) shares declined 2.5 percent on more than three times the average daily volume Thursday to close at $40.18 a share. The company reported a net income of $9.0 million, or $0.19 per diluted share, for the first quarter of 2013, compared with $18.8 million, or $0.40 per diluted share, a year ago.

Find out more about Polypore International including full access to the free equity report at: www.ParagonReport.com/PPO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information